T he aim of this article was to demonstrate two neuroradiologic aspects of local tissue reactions after herpes simplex virus type I thymidine kinase gene / ganciclovir (HSV-Tk /GCV ) system gene therapy with vector producer cells ( VPCs ) in humans, which were visible on systematic MRI follow -up, and discuss the probable pathologic mechanisms and the prognostic relevance of these ''bystander effects.'' We will not discuss the issues of effectiveness, biosafety, and side effects of the treatment.
Somatic gene therapy with the HSV -Tk / GCV system for malignant glioma
The exceptional situation of malignant gliomas as rapid proliferating tumors on the background of the nondividing functional neural tissue in the brain makes them excellently accessible for a selective suicide gene transfer with retroviral vectors. The most common and best investigated antitumor gene therapy strategy for glioma models is the HSV-Tk /GCV system. 1 -3 Despite the relatively low transduction rates, several groups achieved excellent in vivo results and even large tumors regressed completely followed by long -term cure in animal models. 4 -8 Because of the promising results, the first single -center phase I /II studies for human malignant brain tumors were initialized in 1992 in 15 patients with recurrent malignant glioma and metastasis, 9 and in 1994 in 30 patients with recurrent glioblastoma. 10 In 1995, the first international multicenter study started in 48 patients with recurrent glioblastoma 11 and, finally, in 1996 the first randomized international multicenter study was initialized in 246 patients with primary glioblastoma.
The bystander effect
It turned out that the destruction rate of tumor cells (30% to 100% ) exceeded by far the transduction rate ( 1% to 20% ). It was shown that HSV-Tk -positive tumor cells are toxic to nearby unmodified cells when the mixed population is exposed to GCV and this phenomenon was termed the ''kiss of death'' or the bystander effect. 12 -14 The effectiveness of the bystander effect was shown both in vitro and in vivo and complete tumor regression was demonstrated when at least 10% of the cells were transduced. 15 -18 Besides a direct cytotoxic effect of the HSV vector 19 three different hypotheses were discussed to contribute to the antitumor mechanisms of the bystander effect: 20 (1 ) Exchange of toxic metabolites: In vitro and in vivo experiments were able to demonstrate two mechanisms of cell to cell interaction: the transfer of toxic GCV metabolites from HSV-Tk -transduced tumor cells to nearby unmodified cells through gap junctions 21, 22 and the uptake of ''apoptotic'' vesicles containing toxic GCV metabolites from dying GCV-exposed HSVTk -transduced cells to nearby unmodified cells by phagocytosis. 16, 17 (2 ) Compromise of tumor vasculature: In vivo observations demonstrated Tk transfection and necrosis of cycling endothelial cells inducing a hemorrhagic tumor necrosis due to vessel rupture and ischemia. 7, 9, 14, 23 ( 3) Immune responses: In vivo observations in immunocompetent animals suggested that a local inflammatory response of the cellular immune system probably induced by the release of soluble factors like TNF and IL-1 from GCV-exposed HSV-Tk -transduced tumor cells may have an additional antitumor effect. 13, 14, 20, 24 Besides the tumor necrosis, an infiltration of the tumor and the surrounding brain tissue by macrophages and lymphocytes was a constant autopsy finding in animal brains especially after injection of VPCs. Because a severely diminished or lack of bystander effect was shown in immunodeficient animals, particularly in the absence of an intact cellular immune system as in athymic animals, 17, 24, 25 it can be postulated that the cellular immune system may contribute to the effectiveness of the treatment in vivo.
MATERIALS AND METHODS

Patients
Twenty-seven patients with progressive supratentorial single -lesion malignant glioma were treated with VPCmediated HSV-Tk /GCV therapy between March 1996 and September 1998 (treatment group, Table 1 ). Sixteen patients with recurrent tumors who had undergone tumor resection and radiation were included in the study GLIB 201 -E (phase II multicenter study for recurrent glioblastoma, 10 patients, patients 1 to 10), GTI 104 ( phase I /II multicenter study for recurrent malignant glioma in pediatric patients, one patient, patient 15 ), and GTI 117 ( phase III multicenter study for recurrent glioblastoma, five patients, patients 12, 18, 23, 26 and 27 ) . All 16 patients with recurrent tumors underwent resurgery followed by gene therapy. Twenty -one patients with newly diagnosed and previously untreated tumors were included in the study GTI 115 (phase III multicenter randomized study for primary glioblastoma ). Eleven of these patients underwent tumor resection, gene therapy, and postoperative standard radiation ( patients 11, 13, 14, 16, 17, 19 to 22, 24, 25 ) . The remaining 10 patients underwent tumor resection and postoperative standard radiation alone (control group ). Standard radiation therapy was delivered as external beam partial brain radiation with a cumulative dose of 30Â2 Gy over 6 weeks starting 2 to 3 weeks postoperative. All four protocols were sponsored by Novartis Pharma, Nürnberg, Germany.
Within the treatment group there were 10 female and 17 male patients, age range from 14 to 82 with an average of 55.5 years. Karnofsky Performance Scale (KPS ) at admission ranged from 60% to 100% with an average of 81.5%. With the exception of one pediatric patient with an anaplastic ependymoma (AE ) WHO grade III, all patients had glioblastoma multiforme (GB -M ) or gliosarcoma (GS ) WHO grade IV verified by central pathology at the German brain tumor reference center in Bonn.
Treatment strategy
The VPC line used was GLI 328 supplied by Novartis Pharma. 11, 26 The cell suspension was provided by Genetic Therapy (Gaithersburg, MD ) in single -treatment freezing bags, shipped frozen and stored in the vapor phase of liquid nitrogen at the treatment center. The bags were prepared at the day of surgery simultaneously with the tumor debulking procedure to ensure that the VPC preparation was used directly after the surgical procedure without delay. Operative procedure and gene therapy delivery were strictly standardized in all patients. After a debulking procedure with the aim of complete tumor resection, 9 to 10 mL VPC (10 8 mouse fibroblasts /mL ) was injected evenly distributed into the infiltration zone of the surrounding white matter and into the residual tumor in case of subtotal resection. The injections were done free hand at a 3 -to 10 -mm distance from each other, up to a depth of 3 to 15 mm, and in 0.2-mL steps per injection. Two weeks after surgery, patients underwent a 14-day period of intravenous GCV administration (5 mg / kg bid ). All patients received steroid medication (8 to 24 mg Decadrone per day) for at least 4 weeks postoperatively to treat or prevent perifocal edema.
Monitoring
All patients (treatment and control group ) had enhanced MR scans immediately before surgery and systematic postoperative follow -up scans (at least ) at days 1 or 2, 15, 28, weeks 9, 13, 17, 25, 33, and every 8 weeks afterwards. Volumetric evaluation of pre -and postoperative tumor bulk was performed by usage of the local Brainlab neuronavigation system.
There was no systematic tissue sampling (e.g., stereotactic biopsy ) for diagnostic reasons after the treatment and histologic specimens were only collected in case of necessary procedures. Therefore, neuropathologic data could only be obtained in seven patients of the treatment group at different time points after gene therapy during autopsy ( day 27 ) or reoperation for tumor relapse (days 71, 102, 134, 145, 183, and 218 ). The tissue was not taken as small needle biopsy nor excised out of the tumor itself, but collected as multiple representative histologic samples out of the FLOETH, SHAND, BOJAR, ET AL: ''BYSTANDER EFFECT'' IN GENE THERAPY FOR HUMAN GLIOMA resection cavity wall and the adjacent infiltration zone within the white matter.
RESULTS
At the time of this analysis there was no loss of follow -up ( cut -off first of February 2001 ), and patient observation ranged from 29 to 59 months ( Table 1 ) . Twenty -five patients died (92.6% ), 23 ( 85.2% ) because of tumor progression, 1 (3.7% ) due to fatal pulmonary embolism on day 27 (patient 3), and 1 ( 3.7% ) due to unknown reasons without any signs of tumor recurrence at month 8 (patient 13 ). One patient ( 3.7% ), who had local tumor relapse at month 28, was reoperated and was still alive at month 35 ( patient 22). Finally, 1 patient (3,7% ) was actually tumor free without any further treatment at month 59 after the treatment (patient 1). During the peri -and postoperative course no systemic signs of infection or inflammation such as fever, significant changes in differential blood count, or elevation of granulocytes or C -reactive protein were observed.
MR findings
Delayed local hemorrhage. One constant finding was a delayed diffuse and faint local hemorrhage within the injection area and/ or the resection cavity. At day 1 or 2 postoperative no hyperintense signal in the T1 unenhanced images was visible within the operation field indicating absence of blood in the treated area. This continued up to day 13 after injection of the VPC. Immediately after initiation of the GCV administration, starting at day 14, a bright unenhanced T1 signal was detectable within the white matter of the infiltration zone or the resection cavity. This phenomenon most likely represented a diffuse local hemorrhage and was absolutely restricted to the area that was infiltrated by the VPC. It was usually completely absorbed within 2 weeks, not causing any mass effect and clinically inapparent. These microhemorrhages were demonstrable in various intensities in 12 patients of the treatment group (44.4% ), seven times within the parenchyma and five times within the resection cavity ( Fig 1) . None of the 10 patients of the control group exhibited any feature that resembled this local hemorrhagic suffusion. Survival in patients with hemorrhage (n =12; median 13.5 months; range 4 to 59 months) exceeded survival in patients without hemorrhage ( n= 15; median 8 months; range 1 to 16 months), but the distribution of the prognostic factors was different within both subgroups: Patients with hemorrhage were, namely, older ( mean 58.2 years ), but they were in a better state of health (mean KPS 84.2), had smaller residual tumors (mean 3.5 cm 3 ), and had a higher proportion of primary tumors ( 2 recurrences, 10 primary tumors ). Those patients without hemorrhage were on the average younger (mean 53.5 years ), but in a reduced state of health (mean KPS 79.3); they had larger residual tumors (mean 8.5 cm 3 ) and a higher proportion of relapsing tumors (14 recurrences, 1 primary tumor ). According to these data the better survival of the patient group with local hemorrhages can be explained by the favorable distribution of positive prognostic factors alone. Nonmalignant local ''flare'' enhancement. Another finding was a strong local ''flare'' enhancement of 2-to 20 -mm thickness evenly distributed around the resection cavity wall and surrounded by a massive perifocal edema. It arose early within 18 to 72 hours after surgery and VPC injection; the entire process enlarged during the first postoperative weeks and reached a peak after 3 to 5 weeks. Despite a moderate to severe mass effect, which sometimes caused midline shift and compression of the ventricles, this phenomenon was clinically inapparent without any associated signs or symptoms. In the following months the process was characterized by continuous shrinking of the resection cavity, regression of the edema, and slow vanishing of the enhancement. Finally it collapsed and left a small scarry remnant without any enhancement (Figs 2 and 3 ). In addition, enhancing injection tracts were demonstrable, appearing as parallel bright needles radiating from the resection cavity wall deep into the white matter zone (Fig 4 ) . In some cases, the visible depth of the enhancing needle tracts on MRI reached 25 to 30 mm and exceeded the intraoperative assumed depth of the VPC injection. According to the short needle that was used for injection, the maximum depth was calculated to be 15 mm. Depending on the jet pressure of the free -hand injections and the resistance of the tissue, the distribution of the VPC was obviously sometimes much deeper than planned and apparent to the surgeon. This so-called ''flare'' phenomenon of transient dynamically developing local enhancement was demonstrable in various intensities in 13 patients of the treatment group ( 48.2% ). In contrast, none of the 10 patients of the control group exhibited any feature resembling the ''flare'' enhancement.
Patients with absent or weak ''flare'' (enhancement thickness less than 5 mm; n =17 ) constantly had early tumor 
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recurrence or rapid progress of residual tumor (median 2 months) with short survival ( median 8 months; range 4 to 16 months). Patients with strong ''flare'' (enhancement thickness 5 mm or more; n= 10 ) usually had a prolonged relapsefree interval ( median 7 months) with a fair life expectancy ( median 14.5 months; range 1 to 59 months), but again the distribution of the prognostic factors was unequal within both subgroups. The favorable survival data of the patients with a strong ''flare'' can be attributed to their younger age ( mean 52.6 years; mean KPS 81.0 ), smaller residual tumors ( mean 4.1 cm 3 ) and a higher proportion of primary tumors ( five recurrences, five primary tumors ). In contrast, patients with weak or absent ''flare'' enhancement were on an average older ( mean 57.3 years; mean KPS 81.7 ), they had larger tumor remnants after surgery (mean 7.6 cm 3 ), and a higher proportion of relapsing tumors ( 11 recurrences, 6 primary tumors ).
Histological findings
Four infiltration zone features with sequential dominance depending on the period of time after the treatment could be differentiated ( Table 1) . Areas of areactive necrosis near small vessels were observed only in the very early postoperative specimens (days 27 and 71 ). These small necrotic white matter foci appeared to be most likely ischemic and, regarding location and histological features, were clearly different from normal tumor necrosis. The striking finding was an infiltration of the resection cavity wall with inflammatory cells (Fig 5A ) . The early specimens showed a diffuse and very intense macrophage infiltration accompanied by scattered perivascular lymphocytic infiltrations of the otherwise healthy-appearing white matter. This early infiltration with inflammatory cells, based on a combination of resident brain macrophages and migrated blood monocytes, is also termed microglia activation ( Fig  5B ) . Whereas the macrophage infiltration vanished usually within a few weeks, the lymphocyte component became dominant in the further course. The dense perivascular networks consisted nearly exclusively of T lymphocytes ( Fig  5C ) and NK cells, with only a few B lymphocytes intermingled. These perivascular cuffs were a constant finding in all specimens for several months. In the late course, several months postoperative, a marked sarcomatous reaction with large areas of connective tissue formation around the resection cavity could be observed.
It has to be indicated that all these histologic features are not strictly specific findings for gene therapy. Although scattered lymphocytic infiltrations, perivascular T-lymphocyte cuffs, and mesenchymal -glial activation with scar tissue can occur in glioblastoma patients after surgery and radiation alone, the perivascular ischemic necrosis as well as the strong microglia activation are untypical morphologic findings. Also untypical was the location within the white matter zone; changes are usually restricted to the tumor bed and do not involve the surrounding brain in such an intensity.
DISCUSSION
Malignant glioma grow in an extreme infiltrative pattern with scattered migrating microscopic satellites far away from the macroscopically visible tumor bulk. Gene therapy with the HSV-Tk /GCV system via intracerebral injection of mouse fibroblast VPCs was expected to offer the possibility of reaching specifically the tumor cell seed within the infiltration zone, sparing healthy neural tissue. The tumoricidal effect of the therapy is not only restricted to direct apoptotic cell death of transfected glioma cells, but indirect cytotoxic mechanisms to nontransduced cells in the neighbourhood contribute considerably to tumor regression. Only anecdotal information about the mechanism of these bystander effects and their prognostic importance in humans is available. We are able to provide data of a relatively large patient group.
Gene transduction is not restricted to glioma cells as their intended primary target alone, which has been proven in early postoperative biopsies by other authors. 9 We were not able to demonstrate the endothelial cell transfection directly because the ''earliest'' tissue sample within our patient group was obtained at day 27 after the VPC injections (after 13 days of GCV infusion ). At that time all transfected cells had undergone apoptotic cell death due to the therapeutic Tk / GCV suicide mechanism. A direct demonstration of cell transfection is restricted to the period after the VPC injection and before the start of the GCV infusion at day 14. Therefore, we were only able to observe indirect signs of endothelial cell transfection.
Mitotically active endothelial cells of surrounding vessels are also transfected, which consequently causes smallvessel rupture and hemorrhagic necrosis after initiation of GCV treatment. We were able to demonstrate a hyperintense signal within the resection cavity or the surrounding parenchyma in unenhanced T1 scans, which was absent postoperatively and started immediately after the onset of the GCV infusions. This most likely represented delayed local microhemorrhages and was seen in 12 of 27 patients of the treatment group ( 44.4% ), but in none of the 10 patients of the control group. Similar MR features with suspicion for intratumoral hemorrhages were previously reported. 9 The endothelial transfection may lead to vessel necrosis followed by ischemia and hemorrhagic necrosis of adjacent tissue. The potentially corresponding histological findings were areas of areactive necrosis near small vessels, which did not represent tumor necrosis or radiation necrosis, and they were found only in the early postoperative samples. The presence of this kind of local devascularization was not associated with clinical symptoms. In fact survival in patients with secondary hemorrhage (median 13.5 months) was better than in patients without hemorrhage ( median 8 months). But, on the average, the subgroup with local microhemorrhages were privileged by a favorable constellation of prognostic factors such as better performance status, smaller residual tumors, and a higher proportion of primary tumors. Therefore, the appearance of a delayed hemorrhagic suffusion could obviously not be associated with a prognostic benefit and, consequently, it could not serve as an indicator of an increased effectiveness of the treatment.
Additionally it can be assumed that there was an unspecific local inflammatory immune reaction induced by the rejection activity against the xenogenic mouse fibroblast VPCs. This was visible in a transient perifocal enhancement surrounded by a massive edema demonstrable in the MR follow -up of 13 of 27 patients of the treatment group ( 48.2% ) but in none of the 10 patients of the control group. A transient increase of volume of enhancing tissue during the first postoperative weeks followed by a decrease of enhancement, which was termed ''flare'' and considered to reflect an early inflammatory reaction, was shown before by others after VPC gene therapy for malignant glioma in two of seven patients. 27 The term ''flare'' was described first in a study of intratumoral immunotherapy for high -grade glioma with TIL and IL -2, where a transient increase in enhancement and edema was observed. 28 The ''flare'' enhancement can clearly be differentiated from other forms of postoperative enhancement phenomena. The so -called benign postsurgical enhancement is well known to arise after surgical interventions such as tumor resections or brain surgery for seizure control. 29 The characteristics are absence of enhancement in the first 48 to 72 hours, a rise of a linear thin enhancement at the edges of the resection cavity at the end of the first postoperative week, and sustained enhancement for a maximum of 3 months. The discussed underlying mechanisms include disruption of the local blood -brain barrier, formation of neovascularity, and
Cancer Gene Therapy, Vol 8, No 11, 2001 FLOETH, SHAND, BOJAR, ET AL: ''BYSTANDER EFFECT'' IN GENE THERAPY FOR HUMAN GLIOMA luxury perfusion. The knowledge of this phenomenon led to the advice, to perform postoperative scans for assessment of surgical radicality within the first three postoperative days to distinguish between malignant enhancement caused by residual tumor and nonmalignant postsurgical enhancement. 30 There are profound differences between benign postsurgical enhancement and ''flare'' enhancement: Benign postsurgical enhancement arises late and lasts a few weeks, it is only a few millimeters thin, usually not surrounded by a substantial edema and causes no mass shift. In contrast, the ''flare'' reached a thickness of 5 to 20 mm, it arose early within 1 to 3 days after the procedure, and lasted for several months. It was surrounded by a massive edema and induced mass shift, but there was no association with neurological deficits or signs of increased intracranial pressure. Because of the lack of clinical symptoms, fever, and pathologic laboratory values in all patients with ''flare'' enhancement, a local infection, e.g., a brain abscess, as pathologic base, can be ruled out.
In a univariate analysis, ''flare'' seemed to be correlated with patients' outcome: Patients with absent or only weak ''flare'' usually had a very short relapse-free interval and limited survival ( median 8 months). In contrast, patients with early and strong ''flare'' enhancement in general showed an extended relapse-free period and had a relatively good life expectancy ( median 14.5 months). But the patients that exhibited ''flare'' phenomena were privileged by a favorable constellation of prognostic factors like younger age, smaller tumor remnants after surgery, and a higher proportion of primary tumors. Consequently, the appearance of ''flare'' enhancement phenomena was not associated with a better survival and could not serve as an indicator of an increased effectiveness of the treatment.
In the histological specimens, the corresponding finding within this ''flare'' tissue was a strong infiltration of the white matter with inflammatory cells: A diffuse macrophage infiltration of the injected area dominated in the early course and was followed by dense perivascular T-lymphocyte networks during the later course. Similar results were published from two tumor specimens, both obtained 7 days after VPC injection and before GCV infusion, where pockets of perivascular and parenchymal CD -3 positive T-cell infiltrates and moderate numbers of macrophages were seen. 9 The potential of the host immune system for bystander effect-mediated tumor cell killing was highlighted in immunohistochemical studies on tumor tissues from HSVTk suicide gene therapy treated versus control animals. 31 A local inflammatory response leading to a cytokine cascade including TNF -, IL-1, and IL -6 was demonstrated. This subsequently induced an immune response that resulted in an infiltration and tumor cell killing by macrophages and tumor-infiltrating T lymphocytes.
It can be speculated that the injection of the xenogenic mouse fibroblast VPCs deep into the healthy white matter is able to induce a disruption of the intact blood -brain barrier.
Whether it is the traumatic mechanic manipulation of the multiple injections, the xenogenic mouse fibroblasts, the antigenic stimulus of the transduced cells, or a mixture of all these alterations to the surrounding brain that is inducing the inflammatory response remains unclear. In addition, there is no reliable explanation for why some patients developed a very strong ''flare'' reaction and some did not show any radiological changes despite the standardized treatment procedure.
Our results indicate that devascularization and hemorrhagic necrosis due to endothelial cell transfection mediated vessel necrosis and local inflammatory immune responses occur frequently after gene therapy and seem to be an aspect of the bystander effect in humans. These data are concurrent with previous anecdotal descriptions by other authors using the same method. In a univariate analysis, the patients with bystander phenomena after gene therapy on the average have a better outcome: extended life expectancy, longer relapse free period, and some long -term survivors. However, an unbalanced distribution of relevant prognostic factors like age, performance status, and tumor volume, to the advantage of the patient group with devascularization and ''flare'' immune reactions, has to be taken into account. Therefore, their better outcome cannot be attributed to these neuroradiologic features alone. In our group, the appearance of bystander effects after gene therapy was not clearly predictive of the treatment effectiveness or patient outcome.
